Clinical Trial Update: Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

View source ↗

Summary

Bayer is offering expanded access to Sevabertinib (BAY 2927088) for patients with locally advanced or metastatic non-small cell lung cancer harboring HER2 mutat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sevabertinib (sevabertinib)

Snippet

Sponsor: Bayer | Conditions: Advanced Non-small Cell Lung Cancer, Cancer | Status: AVAILABLE